Журнал «Травма» Том 16, №1, 2015

Introduction. Venous disease in the trauma practice - one of the most common pathologies in the world. If in the last century indicated that one or other disorders of venous circulation suffers 15-20% of the population, the data of epidemiological studies in recent years gives a figure of 30-60%. Very often the trauma surgeon in his practice establishes the nature and extent of damage to the segment due to disease or injury, conducts specialized treatment, not paying enough attention to the venous system of the affected limb, which reduces the effectiveness of treatment does not remove all of the patient's complaints. Knowledge of all links in the chain of pathological changes caused by venous insufficiency, helped in the past decade to develop and introduce a new generation of clinical practice phlebotropic drugs with polyvalent mechanism of action, effective impact on the etiology, pathogenesis and symptom of the disease. One such phlebotropic preparations with a polyvalent action is Phleboton® Sopharma, the active ingredient of the drug - Troxerutin (TROXERUTINUM).

Objective: to study the clinical efficacy of oral (capsule) of the drug Phleboton® (Sopharma) in the treatment of venous insufficiency caused by traumatic factors.

Materials and methods. The studies were conducted on the basis of the trauma unit №5 of the Republican Scientific and Practical Center of Traumatology and Orthopedics of Donetsk. During the period from April 2014 to February 2015 was carried out surgical treatment of 40 patients with closed traumatic fractures of the femur and 40 patients with gunshot fractures of the femur were men - 57 (71.3%), women - 23 (28.7%) . The age of patients ranged from 22 to 76 years. The main method of examination of patients was anthropometric - measurement of the circumference of symmetrical segments of the injured limb measuring tape.

Results and discussion. Conducted medical therapy in most cases had a positive impact on the course of the disease. From our point of view, it is more efficient use of the following scheme Phleboton: 600 mg orally, 2 times / day to 14 days, followed by 300 mg once / day to complete relief of symptoms of venous insufficiency. An important step is to evaluate the safety by Phleboton. In 39 patients (97.5%) patients had good or excellent tolerability. In 1 (2.5%) of the study revealed a reaction in the form of headaches and dizziness. In this case, the side effect was not pronounced and did not require discontinuation of the drug.

Conclusions. Results of the study indicate a high clinical efficacy in the treatment of Phleboton venous insufficiency traumatic etiology, particularly in the postoperative period. In assessing the safety Phleboton most patients had excellent or good tolerability and side effects of the available is not of concern for the quality of life of patients and did not require discontinuation of the drug. Thus, the drug Phleboton, having polyvalent mechanism of action, can be used as a base drug in the treatment of venous insufficiency of any origin.